Literature DB >> 18376402

Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation.

Sven Burgdorf1, Christian Schölz, Andreas Kautz, Robert Tampé, Christian Kurts.   

Abstract

Antiviral or antitumor immunity requires activation of cytotoxic CD8+ T cells by dendritic cells, which present viral or tumor antigens on major histocompatibility complex (MHC) class I molecules. The intracellular mechanisms facilitating MHC class I-restricted presentation of extracellular antigens ('cross-presentation') are unclear. Here we demonstrate that cross-presentation of soluble antigen occurred in an early endosomal compartment distinct from the endoplasmic reticulum where endogenous antigen is loaded onto MHC class I. Efficient cross-presentation required endotoxin-induced, Toll-like receptor 4- and signaling molecule MyD88-dependent relocation of the transporter associated with antigen processing, essential for loading of MHC class I, to early endosomes. Transport of cross-presented antigen from endosomes to the cell surface was inhibited by primaquine, which blocks endosomal trafficking. Thus, cross-presentation is spatially and mechanistically separated from endogenous MHC class I-restricted antigen presentation and is biased toward antigens containing microbial molecular patterns.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18376402     DOI: 10.1038/ni.1601

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  183 in total

Review 1.  Control of antiviral immunity by pattern recognition and the microbiome.

Authors:  Iris K Pang; Akiko Iwasaki
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  A proteasome-dependent, TAP-independent pathway for cross-presentation of phagocytosed antigen.

Authors:  Nawel Merzougui; Roland Kratzer; Loredana Saveanu; Peter van Endert
Journal:  EMBO Rep       Date:  2011-12-01       Impact factor: 8.807

Review 3.  Beyond the classical: influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways.

Authors:  Laurence C Eisenlohr; Nancy Luckashenak; Sebastien Apcher; Michael A Miller; Gomathinayagam Sinnathamby
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

Review 4.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 5.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

6.  Steady-state cross-presentation of OVA is mannose receptor-dependent but inhibitable by collagen fragments.

Authors:  Sven Burgdorf; Verena Schuette; Verena Semmling; Katharina Hochheiser; Veronika Lukacs-Kornek; Percy A Knolle; Christian Kurts
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

7.  Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action.

Authors:  Avital Lev; Michael F Princiotta; Damian Zanker; Kazuyo Takeda; James S Gibbs; Chiharu Kumagai; Elizabeth Waffarn; Brian P Dolan; Anne Burgevin; Peter Van Endert; Weisan Chen; Jack R Bennink; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

Review 8.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

Review 9.  Impact of aging on dendritic cell functions in humans.

Authors:  Anshu Agrawal; Sudhir Gupta
Journal:  Ageing Res Rev       Date:  2010-07-07       Impact factor: 10.895

10.  Influenza virus and poly(I:C) inhibit MHC class I-restricted presentation of cell-associated antigens derived from infected dead cells captured by human dendritic cells.

Authors:  Davor Frleta; Chun I Yu; Eynav Klechevsky; Anne-Laure Flamar; Gerard Zurawski; Jacques Banchereau; A Karolina Palucka
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.